×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

·ÅÉäÁÆ·¨ÓÃ×÷·Î°©µÄÖ÷ÒªÖÎÁÆÒªÁ죬±¾Ñо¿Öн¨É迹µçÀë·øÉä·Î°©Ï¸°ûϵµÄ·ÅÉäÖÎÁÆÍ¨¹ý×ðÁú¿­Ê±¾ÙÐÐ

2023-06-28
|
»á¼ûÁ¿£º

13-A549-IR-1.jpg

Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon

The A549 and H1299 cells in exponential growth phase were treated with a repeated IR dose of 2 Gy each at room temperature and then returned to the incubator.

Reference

Kan Wu, et al. Capilliposide C from Lysimachia capillipes Restores Radiosensitivity in Ionizing Radiation-Resistant Lung Cancer Cells Through Regulation of ERRFI1/EGFR/STAT3 Signaling Pathway. Front Oncol. 2021 Apr 1;11:644117. doi: 10.3389/fonc.2021.644117.

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿